Compare OI & ANL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | OI | ANL |
|---|---|---|
| Founded | 1903 | 2004 |
| Country | United States | Singapore |
| Employees | N/A | N/A |
| Industry | Containers/Packaging | |
| Sector | Consumer Discretionary | |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 932.7M | 998.8M |
| IPO Year | 1994 | 2022 |
| Metric | OI | ANL |
|---|---|---|
| Price | $5.94 | $14.18 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 9 | 7 |
| Target Price | $8.81 | ★ $29.50 |
| AVG Volume (30 Days) | ★ 3.7M | 176.6K |
| Earning Date | 10-27-2026 | 08-14-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $6,426,000,000.00 | N/A |
| Revenue This Year | N/A | $243.83 |
| Revenue Next Year | $2.29 | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $5.30 | $0.88 |
| 52 Week High | $16.91 | $17.25 |
| Indicator | OI | ANL |
|---|---|---|
| Relative Strength Index (RSI) | 42.59 | 44.40 |
| Support Level | $5.30 | $12.07 |
| Resistance Level | $9.72 | $15.29 |
| Average True Range (ATR) | 0.23 | 1.27 |
| MACD | 0.08 | -0.17 |
| Stochastic Oscillator | 66.13 | 13.25 |
O-I Glass is the manufacturer of glass containers. The Company has two reportable segments and two operating segments based on its geographic locations: Americas and Europe. Beer is the primary end market for O-I's glass bottles, which are also used for wine, soda, spirits, condiments, and food.
Adlai Nortye Ltd is a clinical-stage company at the forefront of discovering and developing cancer therapies. The company is building a robust pipeline of drug candidates focused on two key areas where it believes it can make a difference RAS-targeting therapies: its is tackling RAS-driven cancers with AN9025, an oral pan-RAS(ON) inhibitor, and AN4035, a CEACAM5-targeting ADC delivering a potent pan-RAS(ON) inhibitor directly to tumors; Next-generation cancer immunotherapies: its candidates, AN8025 (a tri-functional fusion protein of alphaPD-L1 x CD86 variant x LAG3 variant), a T-cell and antigen-presenting cell modulator, and AN4005 (a first-in-class oral small-molecule PD-L1 inhibitor), are designed to activate cancer immunity in novel ways.